Positive (from last week)
• This is for the record as the company reported last week.
• Very strong growth and raised Outlook.
• $3,737bn sales for 9 months +15.0% CER.
• Q3 $1,289 +4.3% ahead of consensus and +21% y/y CER showing acceleration.
• Therapeutic Dermatology was up +40.4% for 9M and +69.1% for Q3 showing that the company is not just about aesthetics. Driven by Numlevio.
• Poised to benefit from "medication-driven weight loss" with Restylane and Sculptra.
• Guidance for full-year sales now +17->+17.7% from (+12-14%) with a slight increase in margins to 23.1-23.6% from ~23%.
Find more articles and bullets on these widgets:
While we heard the monetary policy views of 6 of 12 current FOMC voters this week, there were no real surprises. We go through all of the relevant FOMC communications in full in our Macro Weekly PDF.
2025 FOMC Voters:
Non-2025 Voters:
We've just published our US Macro Weekly - Download Full Report Here
